MBX Biosciences, Inc. (MBX) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGS. Market cap 2.56B USD. 52-week range 12.94 to 72.64 USD. Data as of 2026-10-09.
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that ...